Compare Incyte Corporation (INCY) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs S&P Global Inc — how do they compare? Incyte Corporation trades at $112.8 (market cap $22.85B), while S&P Global Inc trades at $404.47 (market cap $118.72B). The key difference: S&P Global Inc is far larger — about 5.2× Incyte Corporation's market cap, and S&P Global Inc pays a 0.96% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and S&P Global Inc for 123 Days on average.
| INCY | SPGI | |
|---|---|---|
Market Cap | $22.85B | $118.72B |
Volume | 1,927,029 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $129.93 | $517.92 |
52-Week Low | $83.80 | $370.42 |
Typical Hold Time | 33 Days | 123 Days |
Enterprise Value | $18.35B | $130.21B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock shows bearish technical signals but maintains robust fundamentals with 30.5% net margins and consistent revenue growth from $15.3B in 2025 to projected $16.1B in 2026. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The outlook remains positive given the company's dominant market position and financial strength, though technical weakness and high valuation multiples present near-term risks. Long-term growth drivers include AI integration and strategic acquisitions, while risks include market sensitivity to economic cycles and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
